Search form
Search
Login
Subscribe
Home
Country Intelligence
Industry Directory
Offsets / IC
Tenders
Australia
(19/week)
Haiti
(0/week)
Guyana
(0/week)
Honduras
(0/week)
Guatemala
(0/week)
View all
(19/week)
News
United States
(450/week)
Manufacturing
(348/week)
Technology
(352/week)
Energy
(230/week)
Other Manufacturing
(292/week)
Events
About us
Who we are
Our People
Partners
Contact us
LinkedIn
Login
Twitter
Register
Home
News
Apalutamide
Jun 17, 2020
Kangpu to Present Two Posters at the 2020 American Association for Cancer Research (AACR) Annual Meeting
Jun 15, 2020
Global Prostate Cancer Market Analysis to 2028 - Prostate Cancer Market Expected to Increase Despite Generic Abiraterone Entry
May 13, 2020
ERLEADA® (apalutamide) Significantly Improved Overall Survival in Patients with Non-Metastatic Castration-Resistant Prostate Cancer
Feb 03, 2020
Janssen to Highlight Depth of Solid Tumor Portfolio at ASCO GU
Sep 17, 2019
U.S. FDA Approves Supplemental New Drug Application (sNDA) for ERLEADA® (apalutamide) for the Treatment of Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
May 31, 2019
ERLEADA® (apalutamide) Significantly Improved Overall Survival (OS) and Radiographic Progression-Free Survival (rPFS) in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Sep 11, 2018
Health-Related Quality of Life Maintained with Addition of ERLEADA® to Androgen Deprivation Therapy for Patients with Non-Metastatic Castration-Resistant Prostate Cancer
Jul 04, 2018
Health Canada Approves ERLEADA(TM)* (apalutamide tablets), the First Treatment for Men with Non-Metastatic Castration-Resistant Prostate Cancer
Jun 27, 2018
Kangpu Biopharmaceuticals Launched Phase I Study of Novel Cancer Therapy Candidate KPG-121 in Patients with Metastatic Castration-Resistant Prostate Cancer in Collaboration with Accelovance, Inc.
Jun 27, 2018
NucleoBio Concludes Preliminary Tests For New Drug to Treat Aggressive Prostate Cancer
May 18, 2018
ERLEADA(TM) Significantly Reduced Risk of Prostate Specific Antigen (PSA) Progression in Patients with Non-Metastatic Castration-Resistant Prostate Cancer
May 17, 2018
AUA Releases Updates to Clinical Guideline on Castration-Resistant Prostate Cancer
Feb 16, 2018
Global Prostate Cancer Disease Coverage Forecast and Market Analysis 2018-2024: ADT Remains the Most Popular Treatment Choice
Feb 14, 2018
ERLEADA(TM) (apalutamide), a Next-Generation Androgen Receptor Inhibitor, Granted U.S. FDA Approval for the Treatment of Patients with Non-Metastatic Castration-Resistant Prostate Cancer
Feb 08, 2018
Janssen and Johnson & Johnson to Provide Webcast Presentation on Phase 3 Data for Apalutamide and the Janssen Prostate Cancer Strategy and Portfolio
Feb 08, 2018
ERLEADA(TM) (apalutamide), a Next-Generation Androgen Receptor Inhibitor, Lowered Risk of Metastasis or Death in Patients with Non-Metastatic Castration-Resistant Prostate Cancer
Feb 08, 2018
UCSF and MGH: Apalutamide Delays Progression of Nonmetastatic, Castration-Resistant Prostate Cancer
Jan 25, 2018
Janssen to Present 14 Abstracts in Prostate and Urothelial Cancers at ASCO GU 2018, Including New Data on Apalutamide (ARN-509), ZYTIGA® (abiraterone acetate) and Erdafitinib
Dec 21, 2017
U.S. FDA Grants Priority Review to Janssen for Apalutamide as a Treatment for Non-Metastatic Castration-Resistant Prostate Cancer
Oct 11, 2017
Janssen Submits New Drug Application to U.S. FDA for Apalutamide (ARN-509) to Treat Men with Non-Metastatic Castration-Resistant Prostate Cancer
Latest News
Mar 29, 2024
The Next Chapter for Bell’s H-1 Helicopters Begins
Mar 29, 2024
The Next Chapter for Bell’s H-1 Helicopters Begins
Mar 29, 2024
U.S. Army awards BAE Systems $754 million for second phase of full rate production for Armored Multi-Purpose...
Mar 29, 2024
GDIT Awarded $922 Million Contract to Modernize U.S. Central Command IT Infrastructure
Mar 29, 2024
Mitsubishi Electric Announces Director Candidates
Mar 29, 2024
Anaergia Announces Delay in the Filing of Its Audited Financial Statements and Related Disclosures
Mar 29, 2024
Anaergia Announces Escrow Closing of Second Tranche of the Strategic Investment
Mar 29, 2024
Mandalay Resources Corporation Announces Filing of Annual Information Form and Updated NI 43-101 Technical...
View all News
Agenda
17
June
France
Parc des Expositions de Paris Nord Villepinte ZAC Paris Nord 2, 93420 Villepinte – France (Halls 5a – 5b – 6)
Eurosatory 2024, 17 - 21 June 2024, Parc des Expositions de Paris Nord Villepinte ZAC Paris Nord 2, 93420 Villepinte – France (Halls 5a – 5b – 6)
Eurosatory 2024 There can be no sustainable world without peace and security. Founded in 1967, the exhibition...
21
May
Paris Marriott Rive Gauche & Conference Center
Future Artillery, 21-23 May 2024, Paris Marriott Rive Gauche & Conference Center, France
DELIVERING FIRES IN THE MULTI-DOMAIN BATTLESPACE As artillery reasserts itself as the ‘King of Battlefield’ in the wake...
21
May
United Arab Emirates
ADNEC (Abu Dhabi National Exhibition Centre), Abu Dhabi, Al Khaleej Al Arabi St - Al Rawdah - Al Ma'arid - Abu Dhabi, UAE
ISNR Abu Dhabi 2024, 21-23 May 2024, ADNEC (Abu Dhabi National Exhibition Centre), Abu Dhabi, Al Khaleej Al Arabi St - Al Rawdah - Al Ma'arid - Abu Dhabi, UAE
ISNR ACCELERATING TRANSFORMATION IN THE NATIONAL SECURITY ECOSYSTEM ISNR Abu Dhabi is the region’s most trusted...
View All Events